Loading...
•
Dec 31, 2022
Alector Q4 2022 Earnings Report
Alector reported fourth quarter and full year 2022 financial results and provided a corporate update.
Key Takeaways
Alector reported Q4 2022 collaboration revenue of $14.4 million and a net loss of $52.4 million, with cash, cash equivalents, and investments totaling $712.9 million, expected to fund operations through 2025.
On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024.
Preparing to engage with regulatory authorities in mid-2023 and targeting data readout from the pivotal INFRONT-3 clinical trial for latozinemab in early 2025 pending regulatory feedback.
Company and GSK plan to advance AL101 program in 2023, with the initiation of a PK bridging study to be followed by a global Phase 2 clinical trial in early Alzheimer’s disease
$712.9 million in cash, cash equivalents and investments provide runway through 2025
Revenue by Segment
Forward Guidance
Management anticipates, for the year ending 2023, collaboration revenue to be between $15 million and $25 million, total research and development expenses to be between $225 million and $245 million and total general and administrative expenses to be between $60 million and $70 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...